Zoetis Inc Class A (ZTS)

Industry Drug Manufacturers - Specialty & Generic

This stock can be held in an Investment ISA and an Investment Account

Sell

$118.00

Buy

$120.28

arrow-up$1.00 (+0.85%)

Prices updated at 13 Dec 2025, 00:56 EST

Prices minimum 15 mins delay

Prices in USD

Zoetis Inc is a developer and manufacturer of drugs providing medicines for animal health, and vaccines for livestock and companion animals. Its products are anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

S&P 500

-1.07%

NYSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Chairman

Mr. Michael B. McCallister

CEO

Ms. Kristin C. Peck

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

13,800

Head office

10 Sylvan Way

Parsippany

United States

07054

+1 973 822-7000

steve.frank@zoetis.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Ms. Stephanie Tilenius Director	-
Mr. Mark Stetter Independent Director	-
Mr. Gregory Norden Independent Director	0.13m
Ms. Louise M. Parent Independent Director	0.13m
Mr. Michael B. McCallister Non-Executive Chairman of the Board	0.25m
Mr. Paul M. Bisaro Independent Director	0.10m
Mr. Wetteny Joseph Executive Vice President, Principal Accounting Officer and Chief Financial Officer	0.75m
Mr. Frank A. D'Amelio Independent Director	0.11m
Mr. Sanjay Khosla Independent Director	0.10m
Ms. Kristin C. Peck Director and Chief Executive Officer	1.30m
Mr. Gavin D.K. Hattersley Independent Director	0.08m
Ms. Roxanne Lagano Chief Human Resources Officer, Executive Vice President, Global Operations and Interim General Counsel and Corporate Secretary	0.62m
Dr. Willie M. Reed, PhD Independent Director	0.13m
Ms. Antoinette R. Leatherberry Independent Director	0.10m
Ms. Julie Fuller Executive Vice President, Global Operations and Chief Human Resources Officer	-
Dr. Robert J. Polzer, PhD Executive Vice President and President, Research and Development	0.66m
Ms. Jeannette Ferran Astorga Executive Vice President, Corporate Affairs, Communications and Chief Sustainability Officer	-
Ms. Vanessa Broadhurst Independent Director	0.10m
Mr. Jamie Brannan Executive Vice President and Chief Commercial Officer	0.66m
Ms. Rimma Driscoll Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices	-
Mr. Nick Ashton Executive Vice President and President, Global Manufacturing and Supply	-
Mr. Keith Sarbaugh Executive Vice President, Chief Digital Officer and Chief Technology Officer	-
Mr. Jared Shriver President, U.S. Operations	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Vanguard Group Inc	41,886,987
BlackRock Inc	36,198,603
State Street Corp	19,647,509
Morgan Stanley - Brokerage Accounts	16,943,177
State Farm Mutual Automobile Ins Co	15,892,903

Director dealings

Date chevron-l-regular chevron-r-regular	Action
25 Nov 2024	-
25 Nov 2024	-
25 Nov 2024	-
25 Nov 2024	-
25 Nov 2024	-
04 Oct 2024	-
04 Oct 2024	-
04 Oct 2024	-
04 Oct 2024	-
04 Oct 2024	-
04 Oct 2024	-
04 Oct 2024	-
04 Oct 2024	-
03 Sep 2024	-
31 Jul 2024	-
31 Jul 2024	-
31 Jul 2024	-
12 Jul 2024	-
12 Jul 2024	-
12 Jul 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.